Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline

Abstract

A B S T R A C T PurposeTo develop an evidence-based guideline on the use of 5-␣-reductase inhibitors (5-ARIs) for prostate cancer chemoprevention. MethodsThe American Society of Clinical Oncology (ASCO) Health Services Committee (HSC), ASCO Cancer Prevention Committee, and the American Urological Association Practice Guidelines Committee jointly convened a Panel of experts, who used the results from a systematic review of the literature to develop evidence-based recommendations on the use of 5-ARIs for prostate cancer chemoprevention. ResultsThe systematic review completed for this guideline identified 15 randomized clinical trials that met the inclusion criteria, nine of which reported prostate cancer period prevalence. ConclusionAsymptomatic men with a prostate-specific antigen (PSA) Յ 3.0 ng/mL who are regularly screened with PSA or are anticipating undergoing annual PSA screening for early detection of prostate cancer may benefit from a discussion of both the benefits of 5-ARIs for 7 years for the prevention of prostate cancer and the potential risks (including the possibility of high-grade prostate cancer). Men who are taking 5-ARIs for benign conditions such as lower urinary tract [obstructive] symptoms (LUTS) may benefit from a similar discussion, understanding that the improvement of LUTS relief should be weighed with the potential risks of high-grade prostate cancer from 5-ARIs (although the majority of the Panel members judged the latter risk to be unlikely). A reduction of approximately 50% in PSA by 12 months is expected in men taking a 5-ARI; however, because these changes in PSA may vary across men, and within individual men over time, the Panel cannot recommend a specific cut point to trigger a biopsy for men taking a 5-ARI. No specific cut point or change in PSA has been prospectively validated in men taking a 5-ARI. J Clin Oncol 27:1502-1516. This guideline was developed through a collaboration between the American Society of Clinical Oncology and the American Urological Association and has been published jointly by invitation and consent in both the

Survival of Patients with Prostate Cancer in Yazd, Iran

“…Due to our relatively small sample size we were not able to assess the impact of most prevalent tumor patterns on patient survival. There is a growing concern that use of finasteride can increase the number of patients diagnosed with high-grade tumor (Gleason score > 8) (Kramer et al, 2009, Theoret et al, 2011, Thompson et al, 2013. Food and Drug Administration (FDA) issued a change in safety information of the medication, adding the mentioned warning (Thompson et al, 2013).…”

Chemoprevention of Prostate Cancer: Myths and Realities

“…In addition, for those patients who were treated with radical prostatectomy after positive biopsy in PCPT, there was no significant difference between treatment and placebo arms in terms of pathologic stage, nodal involvement, or margin status. 22 Overall, based on results from PCPT, it seems more likely that finasteride increases predictive accuracy of PSA in the detection of prostate cancer and decreases the overall incidence of prostate cancer. Similarly, results from the REDUCE trial seem to support this hypothesis ( Table 1).…”

What we have learned from randomized trials of prostate cancer screening

“…37,38 A recent guideline from the American Society of Clinical Oncology/American Urological Association has encouraged physicians to discuss chemoprevention with men being screened or considering screening for prostate cancer. 39 However, the 5-alpha-reductase inhibitors were associated with an increased risk for high-grade cancers (Gleason scores 7-10). Although post hoc analyses suggested that selection and sampling biases might have spuriously elevated the risk, 40 the guideline acknowledged that these agents still could be inducing aggressive cancers.…”